血脂康对慢性心力衰竭患者心功能及预后影响.doc

血脂康对慢性心力衰竭患者心功能及预后影响[摘要] 目的:研究血脂康对慢性心力衰竭患者心功能及预后的影响。方法:选择慢性心力衰竭患者88例,随机分为对照组(44例)及血脂康治疗组(44例),对照组按心衰常规治疗,治疗组在对照组基础上加服血脂康0.6 g,bid。所有患者治疗前及治疗12个月后查低密度脂蛋白胆固醇(LDL-C)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)及C-反应蛋白(CRP),同时观察患者住院次数、病死率。结果:与治疗前比较,对照组及治疗组LVEDD均明显减小,LVEF均明显升高,对照组LDL-C及CRP无明显变化,治疗组LDL-C及CRP均明显降低。治疗后两组比较,LVEDD、LVEF、CRP及LDL-C均有明显差异,再次住院率及死亡率亦有明显差异。结论:血脂康可改善心力衰竭患者的心功能及预后。 [关键词] 血脂康;慢性心力衰竭;心功能;CRP [中图分类号] R541.6[文献标识码]A [文章编号]1673-7210(2009)07(b)-060-02 Effect of Xuezhikang on heart function and the prognosis in patients with chronic heart failure LIU Ming (Linquan People’s Hospital, Anhui Province, Linquan236400, China) [Abstract] Objective: To study the effect of Xuezhikang on heart function and the prognosis in patients with chronic heart failure. Methods: 88 patients with chronic heart failure were randomly divided into control group(n=44) and Xuezhikang group(n=44). All patients in control group were treated with conventional therapy, Xuezhikang group were added with Xuezhikang 0.6 g, bid. Before and after treatment,the value of LDL-C,LVEF,LVEDD and CRP were measured and the duration of hospitalization and the death rate were analyzed too. Results: After 12 months LVEDD was decreased and LVEF was improved significantly in all patients, LDL-C and CRP were significantly lower in Xuezhikang group than that in control group. LVEDD, LVEF, CRP, LDL-C of Xuezhikang group were significantly different compared with that of control group, the duration of hospitalization and the death rate were significantly different between two groups. Conclusion: Xuezhikang can improve the heart function and prognosis in patients with chronic heart failure. [Key words] Xuezhikang;Chronic heart failure;Heart function;CRP 慢性心力衰竭(chronic heart failure,CHF)是大多数心血管疾病的最终归宿,也是最主要的死亡原因。随着人口的老龄化,CHF的发病率、死亡率逐年上升。4S和CARE的亚组分析中发现,他汀类药物组和安慰剂组进行比较,CHF的新发率可减少20%[1-2],提示他汀类药物可能对CHF患者有益。本文旨在探讨血脂康能否改善CHF患者心功能及预后。 1 资料与方法 1.1 一般资料 选择2004年1月～2008年6月我院门诊或住院的初次诊断为CHF的患者88例,所有患者均符合Fr